Become a member today. It's free.
We will not release or resell your information to third-parties without your permission.
After a decade of neglect
Many blockbuster drugs will lose their patent exclusivity
Should be stashing cash and making acquisitions
Pfizer’s revenues in 3Q13 were better than expectations. The company’s stock price rose 1.7% after the earnings release as the company...
really, I would say it is not really expnesive. It will be expensive when fails to generate revenues and profits.
Pfizer has performed better than Merck and the reason for decline earnings + sales is patent expiry.
I have been trading PFE on and off for a long time and without these updates I don't think I would have known how to flip it for huge...
The flagship S&P 500 is hitting all kinds of technical and sentimental extremes only seen at major toppings. Euphoria now reigns supreme...